Search Immortality Topics:

Page 20«..10..19202122..3040..»


Category Archives: Global News Feed

Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales…

PALO ALTO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced monthly revenue in November 2023 and provided certain preliminary unaudited financial results for gross and net sales for the one month ended November 2023 and year-to-date through November 30, 2023.

Go here to read the rest:
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales...

Posted in Global News Feed | Comments Off on Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales…

Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.

Read the original here:
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

Posted in Global News Feed | Comments Off on Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant…

NRTX-1001 investigational treatment has been well tolerated in all initial subjects

Read this article:
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant...

Posted in Global News Feed | Comments Off on Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant…

RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO

Virender Ahluwalia will serve as Interim Chief Financial Officer Virender Ahluwalia will serve as Interim Chief Financial Officer

Continued here:
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO

Posted in Global News Feed | Comments Off on RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO

Number of voting rights as of November 30, 2023

Nicox SA Société anonyme with a registered capital of € 50,170,498

More:
Number of voting rights as of November 30, 2023

Posted in Global News Feed | Comments Off on Number of voting rights as of November 30, 2023

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated Information

Read more from the original source:
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Posted in Global News Feed | Comments Off on Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC